Signal active
Investment Firm
Overview
GSK is a science-led global healthcare company that researches and develops a broad range of innovative medicines and brands. Their products are used by millions of people around the world, helping them to do more, feel better and live longer.
Highlights
2000
Venture Capital
10001+
17
2
5
Late Stage Venture, Early Stage Venture, Seed
Venture Capital
Location
Kelayres, Pennsylvania, United States, North America
Contact Information
Social
Profile Resume
GSK, established in 2000 and headquartered in United States, North America., specializes in Late Stage Venture, Early Stage Venture, Seed investments across Biotechnology, Health Care, Pharmaceutical, Medical, Venture Capital, Finance, Business Development, Photography, Angel Investment, Financial Services. The organization boasts a portfolio of 17 investments, with an average round size of $23.3M and 5 successful exits. Their recent investments include Concert Pharmaceuticals, Flagship Pioneering, Brookside Capital, Skyline Ventures, Three Arch Partners. The highest investment round they participated in was $31.8B. Among their most notable exits are Concert Pharmaceuticals and Flagship Pioneering. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
17
7
2
5
Investments
17
Annouced Date | Organization Name | Industry | Money Raised |
---|---|---|---|
Apr 05, 2023 | Patientory | Software | 1.5M |
Sep 27, 2023 | - | - | 39.0M |
May 07, 2024 | - | - | 13.5M |
May 14, 2024 | Elegen | Biotechnology | 35.0M |
Exits
5
Funding Timeline
17
0
0
Funding Rounds
17
GSK has raised 17 rounds. Their latest funding was raised on May 14, 2024 from a Series B - Elegen round.
Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
---|---|---|---|---|
Apr 05, 2023 | Seed Round - Patientory | - | 1.5M | - |
Sep 27, 2023 | Series A - Sitryx Therapeutics | - | 39.0M | - |
May 07, 2024 | Series C - BioVersys | - | 13.5M | - |
May 14, 2024 | Series B - Elegen | - | 35.0M | - |
Investors
0
There is no funding round available on this profile
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
Annouced Date | Fund Name | Money Raised |
---|---|---|
May 10, 2013 | OTPPLESS | 1.0M |
May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
News
Sep 24, 2024
MarketScreener - GSK: positive opinion from the European CHMP
News
Sep 24, 2024
thefly.com - GSK's Menveo vaccine receives positive European CHMP opinion
News
Sep 23, 2024
Endpoints News - UK vaccine startup Vicebio snags $100M to take on GSK, Pfizer and Moderna
News
Sep 19, 2024
pharmaphorum - ICER mulls GSK COPD drugs ahead of next Medicare negotiation
News
Sep 18, 2024
Investing.com - GSK settles two California lawsuits related to heartburn drug Zantac
News
Sep 18, 2024
MarketScreener - GSK reaches further two settlements regarding Zantac